Physician profile
Maud Aryee
NPI 1588179477
$859.13
in general payments reported to CMS, 2019-2025
11 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.76 · 2022: $311 · 2023: $216 · 2024: $20.79 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $166.85 | 2021-2025 | Sublocade |
| Gilead Sciences, INC. | $144.86 | 2023 | Epclusa |
| Neurocrine Biosciences, INC. | $126.62 | 2025 | |
| Boston Scientific Corporation | $89.38 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $80.74 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.11 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.02 | 2022 | |
| Alkermes, INC. | $45.87 | 2021-2025 | Vivitrol, Vivitrol |
| Redhill Biopharma INC. | $42.92 | 2021 | |
| Abbvie INC. | $38.97 | 2022 | |
| Vertos Medical, INC. | $20.79 | 2024 | Mild Device Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maud Aryee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.